BioXcel Therapeutics, Inc. (BTAI) DCF Valuation

BioXcel Therapeutics, Inc. (BTAI) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

BioXcel Therapeutics, Inc. (BTAI) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our BioXcel Therapeutics, Inc. (BTAI) DCF Calculator enables you to assess the valuation of BioXcel Therapeutics, Inc. with up-to-date financial data and complete flexibility to modify all essential parameters for improved projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .4 1.4 1.7 2.2 2.7 3.4 4.2
Revenue Growth, % 0 0 0 0 268 25 25 25 25 25
EBITDA -32.8 -82.0 -107.0 -157.4 -165.4 .3 .4 .5 .7 .8
EBITDA, % 100 100 100 -41969.07 -11987.03 20 20 20 20 20
Depreciation .2 .2 .3 .3 .3 1.4 1.8 2.2 2.8 3.5
Depreciation, % 100 100 100 87.2 23.04 82.05 82.05 82.05 82.05 82.05
EBIT -33.0 -82.2 -107.3 -157.7 -165.7 .3 .4 .5 .7 .8
EBIT, % 100 100 100 -42056.27 -12010.07 20 20 20 20 20
Total Cash 32.4 213.1 233.0 193.7 65.2 1.7 2.2 2.7 3.4 4.2
Total Cash, percent .0 .0 .0 .1 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .2 .1
Account Receivables, % 100 100 100 66.13 5.14
Inventories .0 .0 .0 2.0 2.0 1.7 2.2 2.7 3.4 4.2
Inventories, % 100 100 100 529.33 144.28 100 100 100 100 100
Accounts Payable 5.0 4.0 4.7 10.2 13.7 1.7 2.2 2.7 3.4 4.2
Accounts Payable, % 100 100 100 2727.47 989.42 100 100 100 100 100
Capital Expenditure -.9 -.3 -.4 -.1 .0 -.1 -.2 -.2 -.3 -.3
Capital Expenditure, % 100 100 100 -37.07 -1.45 -7.7 -7.7 -7.7 -7.7 -7.7
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -32.3 -82.0 -107.0 -163.5 -165.7 .3 .4 .5 .7 .8
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -28.1 -83.1 -106.4 -160.0 -161.8 -11.2 1.7 2.1 2.7 3.3
WACC, % 12.16 12.37 12.36 12.39 12.39 12.33 12.33 12.33 12.33 12.33
PV UFCF
SUM PV UFCF -3.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 3
Terminal Value 33
Present Terminal Value 18
Enterprise Value 15
Net Debt 36
Equity Value -21
Diluted Shares Outstanding, MM 29
Equity Value Per Share -0.73

What You Will Get

  • Real BTAI Financial Data: Pre-filled with BioXcel Therapeutics’ historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See BioXcel Therapeutics’ intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive Data: BioXcel Therapeutics' historical financial statements and pre-filled projections.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
  • Real-Time Insights: Monitor BioXcel Therapeutics' intrinsic value as it updates instantly.
  • Visual Analytics: Dashboard visualizations showcase valuation outcomes and essential metrics.
  • Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.

How It Works

  • Step 1: Download the prebuilt Excel template featuring BioXcel Therapeutics, Inc. (BTAI) data.
  • Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Immediately see the recalculated results, including BioXcel Therapeutics, Inc.'s (BTAI) intrinsic value.
  • Step 5: Make well-informed investment choices or create reports based on the outputs.

Why Choose the BioXcel Therapeutics Calculator?

  • Accuracy: Utilizes real BioXcel financial data for precise calculations.
  • Flexibility: Allows users to easily adjust and test different input variables.
  • Time-Saving: Eliminate the need to create a financial model from the ground up.
  • Professional-Grade: Crafted with the expertise and standards expected by financial professionals.
  • User-Friendly: Intuitive interface suitable for users with varying levels of financial knowledge.

Who Should Use BioXcel Therapeutics, Inc. (BTAI)?

  • Investors: Make informed investment choices with insights from a pioneering biopharmaceutical company.
  • Healthcare Analysts: Streamline your research with detailed reports on innovative therapies and market potential.
  • Consultants: Easily modify data for client presentations or strategic assessments in the biotech sector.
  • Biotech Enthusiasts: Expand your knowledge of cutting-edge drug development and its impact on patient care.
  • Educators and Students: Utilize it as a real-world case study in biotechnology and pharmaceutical courses.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled BioXcel Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for BioXcel Therapeutics, Inc. (BTAI).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.